Glenmark Readying Xolair Biosimilar Challenge
Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.
You may also be interested in...
Sorrento Therapeutics has gained exclusive licensing rights from China’s Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China’s homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.